India approves Takeda's dengue vaccine Qdenga for ages 4 to 60

In July 2026, India’s Central Drugs Standard Control Organisation (CDSCO) granted approval for Takeda’s Qdenga dengue vaccine, marking a significant milestone in the country’s public health strategy. This vaccine is authorized for individuals aged four to sixty and represents a new approach to dengue prevention. The decision follows a comprehensive review of clinical evidence, which included a study featuring Indian participants. Although the vaccine will be available in India’s private market starting in the first half of 2027, the approval opens new avenues for protection against dengue fever, which poses a considerable health threat in many regions.

The Qdenga vaccine is designed to combat dengue disease caused by four distinct virus types: DENV-1, DENV-2, DENV-3, and DENV-4. It is administered in two doses, with a 0.5ml injection given under the skin three months apart. The health ministry confirmed that the vaccine's efficacy was demonstrated through a late-stage trial, which reported 80.2% effectiveness against laboratory-confirmed dengue in the first year and 90.4% against dengue-related hospitalizations over an 18-month period. This data highlights the vaccine's potential to significantly reduce the burden of dengue in India.

The implementation of Qdenga's distribution will involve a collaboration between Takeda and Dr. Reddy’s Laboratories, which will promote and distribute the vaccine through private healthcare providers. However, it is important to note that regulatory approval does not equate to immediate availability for vaccinations; further local procedures will need to be completed. Additionally, while Takeda retains the rights to supply the public market, any inclusion in government immunization programs will require separate policy decisions by health authorities.

The broader implications of Qdenga’s approval are substantial, particularly given the high burden of dengue in India. In 2024, the country reported over 232,000 dengue cases and 233 fatalities due to the disease, underscoring the urgent need for effective preventive measures. By introducing Qdenga, India aims to enhance its public health response to dengue, which is transmitted by infected mosquitoes and can lead to severe health complications.

The approval of this vaccine is a critical step in addressing the ongoing challenge of dengue fever and improving health outcomes for the population. Looking toward the future, the rollout of Qdenga will need to be carefully managed to maximize its impact on public health. As India navigates the introduction of this vaccine, considerations will include prioritizing which populations should receive it and ensuring robust public health measures remain in place, such as mosquito control and prompt treatment of infections. The successful deployment of Qdenga could serve as a model for addressing other vector-borne diseases in the region, marking a significant development in global health efforts.